Investigation of the antiviral activity of an oral drug preparation based on immobilized interferon λ-1
https://doi.org/ 10.15372/SSMJ20180304
Abstract
Despite the success in developing direct-acting antiviral drugs, in routine clinical practice the use of interferons remains relevant. Parenteral administration of interferons is accompanied by systemic side effects and presents significant inconveniences for patients. A drug based on interferon λ-1, which has high enteric bioavailability and ensures its high concentration in the liver, is promising for the effective treatment of hepatotropic viruses. The aim of the investigation was to study the antiviral activity of an oral medicine based on interferon λ-1 immobilized on polyethylene glycol-1500 by electron-beam synthesis technology. Materials and methods: Real time PCR, Western blot and immunohistochemical method were used to study antiviral activity of tested medicine against hepatitis C virus. Results and discussion: The tested medicine retains antiviral activity against hepatitis C virus. All obtained results are consistent with each other. A 50 % inhibitory dose is in the range of 0.008-0.08 ng/ml. Conclusion: IFN λ-1 immobilized on polyethylene glycol with the help of radiation synthesis technology can be considered as a prototype of an oral drug for the treatment of viral hepatitis, in particular hepatitis C.
About the Authors
D. N. Kinsht
Novosibirsk State Medical University of Minzdrav of Russia; «Scientific Future Management» company
Russian Federation
Russian Federation
P. G. Madonov
Novosibirsk State Medical University of Minzdrav of Russia «Scientific Future Management» company Novosibirsk State Medical University of Minzdrav of Russia; «Scientific Future Management» company
Russian Federation
Russian Federation
G. V. Kochneva
State Research Center of Virology and Biotechnology «Vector»
Russian Federation
Russian Federation
T. S. Tartynova
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
G. I. Baykalov
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
References
1. Киншт Д.Н., Мадонов П.Г., Святченко В.А., Терновой В.А. Экспериментальное обоснование применения пероральной формы пегилированного интерферона α2-b для терапии энтеровирусной инфекции // Сиб. науч. мед. журн. 2017. 37. (3). 11-16.
2. Мадонов П.Г., Ершов К.И., Дубровин А.В., Заполоцкий Е.Н., Мирошников П.Н., Шилова М.А., Киншт Д.Н. Электронно-лучевая модификация препаратов белковой природы для улучшения их фармакологических свойств // Мед. и образ. в Сибири. 2013. (4). Режим доступа: http://ngmu.ru/cozo/mos/article/text_full.php?id=1115. Дата обращения: 08.11.2017.
3. Пат. 2409669 РФ. Способ иммобилизации биологически активных веществ на полимерных носителях (варианты) и конъюгаты, полученные данным способом / А.В. Артамонов, А.А. Бекарев, Е.И. Верещагин; Опубл. 20.01.2011.
4. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., Rice C.M. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics // Gastroenterology. 2006. 131. 1887-1898.
5. Veronese F.M., Pasut G. Protein PEGylation // Long acting injections and implants / Eds. J.C. Wright, D.J. Burgess. N.Y.; Dordrecht; Heidelberg; L.: Springer, 2012. 295-314.
Review
For citations:
Kinsht D.N., Madonov P.G., Kochneva G.V., Tartynova T.S., Baykalov G.I. Investigation of the antiviral activity of an oral drug preparation based on immobilized interferon λ-1. Сибирский научный медицинский журнал. 2018;38(3):30-34. (In Russ.) https://doi.org/ 10.15372/SSMJ20180304
Views:
382
Email this article 